PHP
RYTM icon

Parkman Healthcare Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Parkman Healthcare Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-157,862
Closed -$4.6M – 92
2022
Q4 		$4.6M Sell
157,862
-30,127
-16% -$774K 1.22% 32
2022
Q3 		$4.61M Buy
+187,989
New +$3.5M 1.31% 25

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Parkman Healthcare Partners's RYTM Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2023, closing a stake of 157,862 shares — an estimated $4.6M sold.

Parkman Healthcare Partners first reported a position in RYTM in Q3 2022 and held it in 2 quarters. The position peaked at $4.61M in Q3 2022. 126 funds tracked by Wall St. Rank hold RYTM as of Q1 2023.

  • Parkman Healthcare Partners reported no remaining Rhythm Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 157,862 Rhythm Pharmaceuticals shares in Q1 2023, an estimated $4.6M.
  • Parkman Healthcare Partners first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Parkman Healthcare Partners's Rhythm Pharmaceuticals position peaked at $4.61M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.